Clinical trial CABL001J12301
A Phase III, multi-center, open-label, randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase
| Cancers | |
|---|---|
| Organ | LMC |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Novartis |
| EudraCT Identifier | 2021-000678-27 |
| Inclusion criteria | 1.Male or female patients ? 18 years of age.2.Patients with CML-CP within 3 months of diagnosis*3.Diagnosis of CML-CP with cytogenetic confirmation of Philadelphia chromosome of (9;22) translocations (presence of BCR-ABL1 in a review of a minimum 20 m |
| Last update |